✨ Onyx Summary MassBio will host the 2025 Patient Advocacy Summit on November 6 at the MassBioHub, themed “Purpose, In Spite of Pressure,” highlighting how patients and advocates drive progress across the healthcare and drug development landscape. The event will feature a keynote by Yelak Biru and Fatima Scipione on the
“Around 80 percent of payments in agriculture are still paper checks. We’re literally burning gasoline to move paper,” Jake Joraanstad calls out the analog inefficiencies undermining agriculture’s bottom line.
✨ Onyx Summary Perspective Therapeutics announced that the first patient has been treated in the second cohort of its Phase 1/2a trial evaluating [212Pb]PSV359, a targeted alpha radiopharmaceutical for solid tumors expressing FAP-α. The study advances dose escalation to 5.0 mCi following favorable safety review at lower doses,
All the details on when the 44th annual J.P. Morgan Healthcare Conference takes place!
✨ Onyx Summary Ocugen will present at the 2025 Cell & Gene Meeting on the Mesa (Oct. 6, Phoenix), Chardan’s 9th Annual Genetic Medicines Conference (Oct. 21, New York), and the 2025 Maxim Growth Summit (Oct. 22, New York) to outline progress toward its goal of three BLAs in the
"Reducing our own footprint matters greatly, but the biggest point of impact is what our products can do; how they enhance sustainability when our customers use them; or when consumers use the products that our ingredients go into.”
✨ Onyx Summary enGene Holdings granted inducement equity awards to four new employees, including Chief Medical Officer Hussein Sweiti, M.D., MSc, with options to purchase a total of 657,950 common shares at an exercise price of $6.83 per share. The grants, made under Nasdaq Listing Rule 5635(c)
"I can tell Starbucks the exact number of their containers that came through - down to whether they came from a resident or a commercial business,” Tim Stuart shows how AMP’s AI turns data on trash into corporate sustainability insights.
✨ Onyx Summary enGene Holdings appointed Hussein Sweiti, M.D., MSc, as Chief Medical Officer, effective September 29, 2025. Dr. Sweiti, formerly Global Medical Head of Oncology Clinical Development at Johnson & Johnson, joins enGene as it transitions detalimogene voraplasmid toward regulatory filing and potential commercialization in high-risk, BCG-unresponsive non-muscle invasive
✨ Onyx Summary Massachusetts biotech leaders emphasized the importance of balancing drug affordability initiatives with the need to sustain innovation that drives future cures. As federal policymakers weigh new cost-control measures, the statement underscores that safeguarding both access and discovery is vital to ensure patients benefit not only from lower prices
✨ Onyx Summary Saama announced the launch of modular Clinical AI Agents built on its Agentic AI platform, enabling sponsors to drive efficiency and innovation across the clinical development lifecycle through partial autonomy and human-in-the-loop oversight. The purpose-built system addresses integration and compliance failures seen in generalist AI models, offering adaptable,
"Nickel stays nickel, lithium stays lithium. If you recycle down to the elemental level, you can build them back up again and again - indefinitely,” Ryan Melsert reveals why elemental recovery is the foundation for a resilient battery supply chain.
✨ Onyx Summary Guardant Health announced FDA approval of its Guardant360® CDx as a companion diagnostic for Eli Lilly’s Inluriyo (imlunestrant), enabling identification of advanced or metastatic ER+, HER2– breast cancer patients with ESR1 mutations who may benefit from the therapy. This marks the test’s sixth FDA-approved companion diagnostic
"Almost a third of over-65s will fall each year," but could nGVS represent a discreet tool against imbalance?
"Second-hand in the U.S., and globally, is projected to nearly double by 2030. The short answer is that the world needs more resale,” ThredUp's James Reinhart reveals how partnerships, tech, and trust are fueling the recommerce boom.
"Anybody can be a shipowner if they can raise the capital. What sets you apart is the organization you build around the ships,” Gernot Ruppelt highlights why culture and execution matter as much as fleet size in today’s tanker trade.
